Literature DB >> 17125467

Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway.

Shen Kiat Lim1, Ganesan Gopalan.   

Abstract

Mitotic Aurora-A is an oncogene, which undergoes a cell-cycle-dependent regulation of both its synthesis and degradation. Overexpression of Aurora-A leads to aneuploidy and cellular transformation in cultured cells. It has been shown that the cell-cycle-dependent turnover of Aurora-A is mediated by Cdh1 (CDC20 homologue 1) through the anaphase-promoting complex/cyclosome (APC/C)-ubiquitin-proteasome pathway. We have described previously the identification of an Aurora-A kinase interacting protein, AURKAIP1 (formerly described as AIP), which is also involved in the destabilization of Aurora-A through the proteasome-dependent degradation pathway. In an attempt to investigate the mechanism of AURKAIP1-mediated Aurora-A degradation, we report here that AURKAIP1 targets Aurora-A for degradation in a proteasome-dependent but Ub (ubiquitin)-independent manner. AURKAIP1 inhibits polyubiquitination of Aurora-A. A non-interactive AURKAIP1 mutant that cannot destabilize Aurora-A restores ubiquitination of Aurora-A. An A-box mutant of Aurora-A, which cannot be targeted for proteasome-dependent degradation by Cdh1, can still be degraded by AURKAIP1. Inhibition of cellular ubiquitination either by expression of dominant negative Ub mutants or by studies in ts-20 (temperature sensitive-20) CHO (Chinese-hamster ovary) cell line lacking the E1 Ub activating enzyme at the restrictive temperature, cannot abolish AURKAIP1-mediated degradation of Aurora-A. AURKAIP1 specifically decreases the stability of Aurora-A in ts-20 CHO cells at the restrictive temperature, while cyclinB1 and p21 are not affected. This demonstrates that there exists an Ub-independent alternative pathway for Aurora-A degradation and AURKAIP1 promotes Aurora-A degradation through this Ub-independent yet proteasome-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17125467      PMCID: PMC1828899          DOI: 10.1042/BJ20061272

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Degradation of ornithine decarboxylase in reticulocyte lysate is ATP-dependent but ubiquitin-independent.

Authors:  Z Bercovich; Y Rosenberg-Hasson; A Ciechanover; C Kahana
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

Review 2.  Ubiquitin-independent proteolytic functions of the proteasome.

Authors:  Marian Orlowski; Sherwin Wilk
Journal:  Arch Biochem Biophys       Date:  2003-07-01       Impact factor: 4.013

3.  Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway.

Authors:  K Honda; H Mihara; Y Kato; A Yamaguchi; H Tanaka; H Yasuda; K Furukawa; T Urano
Journal:  Oncogene       Date:  2000-06-01       Impact factor: 9.867

4.  Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome.

Authors:  I Jariel-Encontre; M Pariat; F Martin; S Carillo; C Salvat; M Piechaczyk
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

5.  MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.

Authors:  Patima Sdek; Haoqiang Ying; Donny L F Chang; Wei Qiu; Hongwu Zheng; Robert Touitou; Martin J Allday; Zhi-Xiong Jim Xiao
Journal:  Mol Cell       Date:  2005-12-09       Impact factor: 17.970

6.  The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor.

Authors:  G J Strous; P van Kerkhof; R Govers; A Ciechanover; A L Schwartz
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

7.  Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.

Authors:  R J Sheaff; J D Singer; J Swanger; M Smitherman; J M Roberts; B E Clurman
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

8.  Degradation of CFTR by the ubiquitin-proteasome pathway.

Authors:  C L Ward; S Omura; R R Kopito
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

9.  P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.

Authors:  Gad Asher; Joseph Lotem; Peter Tsvetkov; Veronica Reiss; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

10.  MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.

Authors:  Yetao Jin; Hunjoo Lee; Shelya X Zeng; Mu-Shui Dai; Hua Lu
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

View more
  18 in total

1.  p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation.

Authors:  Chun-Chi Wu; Tsung-Ying Yang; Chang-Tze Ricky Yu; Liem Phan; Cristina Ivan; Anil K Sood; Shih-Lan Hsu; Mong-Hong Lee
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

Review 2.  Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.

Authors:  Giulia Bertolin; Marc Tramier
Journal:  Cell Mol Life Sci       Date:  2019-09-27       Impact factor: 9.261

3.  Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma.

Authors:  E C Torchia; C Caulin; S Acin; T Terzian; B J Kubick; N F Box; D R Roop
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

4.  Breast Cancer Risk Associated with Genotype Polymorphisms of the Aurora Kinase a Gene (AURKA): a Case-Control Study in a High Altitude Ecuadorian Mestizo Population.

Authors:  Andrés López-Cortés; Alejandro Cabrera-Andrade; Fabián Oña-Cisneros; Carolina Echeverría; Felipe Rosales; Malena Ortiz; Eduardo Tejera; César Paz-Y-Miño
Journal:  Pathol Oncol Res       Date:  2017-06-24       Impact factor: 3.201

5.  ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.

Authors:  Aurélie Thollet; Julie A Vendrell; Léa Payen; Sandra E Ghayad; Sabrina Ben Larbi; Evelyne Grisard; Colin Collins; Marie Villedieu; Pascale A Cohen
Journal:  Mol Cancer       Date:  2010-11-08       Impact factor: 27.401

Review 6.  When 2+2=5: the origins and fates of aneuploid and tetraploid cells.

Authors:  Randall W King
Journal:  Biochim Biophys Acta       Date:  2008-08-07

Review 7.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

8.  The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

Authors:  Xin Hong; James P O'Donnell; Clarence R Salazar; James R Van Brocklyn; Kahlil D Barnett; Dennis K Pearl; Ana C deCarvalho; Jeffrey A Ecsedy; Stephen L Brown; Tom Mikkelsen; Norman L Lehman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-14       Impact factor: 3.333

9.  Myocardin-related transcription factor and serum response factor regulate cilium turnover by both transcriptional and local mechanisms.

Authors:  Pam Speight; Matthew Rozycki; Shruthi Venugopal; Katalin Szászi; Michael Kofler; András Kapus
Journal:  iScience       Date:  2021-06-17

Review 10.  The Non-Canonical Role of Aurora-A in DNA Replication.

Authors:  Takaaki Tsunematsu; Rieko Arakaki; Akiko Yamada; Naozumi Ishimaru; Yasusei Kudo
Journal:  Front Oncol       Date:  2015-08-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.